ArticleBMC pediatrics2026
Extreme hyperleukocytosis and blueberry muffin skin lesions as the initial presentation of neonatal leukemia: a case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal leukemia is a rare and aggressive hematologic malignancy, accounting for less than 1% of pediatric leukemias. Mixed phenotype acute leukemia (MPAL) is particularly uncommon in this age group and poses significant diagnostic and therapeutic challenges. Hyperleukocytosis and leukostasis are life-threatening complications requiring urgent intervention. CASE PRESENTATION: We report the case of a 7-day-old male neonate, small for gestational age, who presented with extreme hyperleukocytosis (peak leukocyte count: 615,400/µL), severe anemia, thrombocytopenia, and generalized purpuric skin lesions consistent with blueberry muffin syndrome. The clinical course was complicated by coagulopathy and a high risk of tumor lysis syndrome. Cytoreductive management included manual partial exchange transfusion due to the unavailability of leukapheresis, achieving transient leukoreduction. Flow cytometry identified two abnormal populations: B-lineage blasts expressing CD19, CD79a, and cytoplasmic CD22, and a myeloid/monocytic population expressing myeloperoxidase (MPO), CD13, and CD33. Lineage assignment was established according to World Health Organization (WHO, 5th edition) and International Consensus Classification (ICC) lineage-defining criteria, confirming MPAL, B/myeloid subtype. Cytogenetic analysis revealed a karyotype 46,XY, add(19)(p13), while molecular testing for KMT2A rearrangements and other recurrent fusion genes was negative. Induction chemotherapy was initiated after initial stabilization; however, the patient died 45 days after diagnosis due to disease progression.
conclusionThis case highlights the diagnostic complexity and aggressive clinical course of neonatal MPAL, particularly in the absence of KMT2A rearrangements, and emphasizes the biological heterogeneity of this entity. Strict application of WHO/ICC lineage-defining criteria is essential to ensure accurate classification. Exchange transfusion may serve as a feasible bridging cytoreductive strategy in neonates with life-threatening hyperleukocytosis when leukapheresis is not available, although its effects are temporary and do not replace definitive therapy. Early recognition, prompt supportive management, and improved molecular characterization are critical to optimizing outcomes in this rare and high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.